Company intelligence / Profile preview

Suzhou Furong Biotechnology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Three clinical trials ongoing or recruiting: FL115 monotherapy and combinations (monotherapy recruitment, safety/tolerability/dose escalation in metastatic solid tumors, Phase I); FL115 + PD-1 monoclonal antibody (combination with Sintilimab, Phase 1/2 recruiting for advanced solid tumors); FL115 intravesical and FL115 + BCG (Phase 1/2 recruiting for non-muscle invasive bladder cancer). No published efficacy results yet; safety/tolerability studies underway as of 2025

Therapeutic areas: OncologyEndocrinology
Modalities: Fusion proteinBiological productsCytokine
Industry: Biotech

Partnerships

Clinical trials with Sintilimab (PD-1 inhibitor)

Beyond the preview

Go deeper on Suzhou Furong Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Furong Biotechnology.

Explore the full profile